A clinical trial sponsored by the World Health Organization has begun enrolling patients with the Bundibugyo strain of Ebola in Congo's Ituri province to test Mapp Biopharmaceutical’s MBP134 monoclonal antibody cocktail and Gilead Sciences’s remdesivir alongside optimized supportive care. The adaptive platform trial is designed to continue across future outbreaks if needed. The current outbreak has killed more than 500 people and infected nearly 1,600 across Congo and Uganda.